Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE SODIUM 20 versus HYPAQUE M 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE SODIUM 20 versus HYPAQUE M 75.
HYPAQUE SODIUM 20% vs HYPAQUE-M,75%
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Hypaque sodium is an ionic monomeric iodinated contrast medium that absorbs X-rays due to its iodine content, providing radiographic contrast. It increases the density of vascular structures and organ parenchyma, allowing visualization during imaging procedures.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast due to high iodine content. It increases the density of vascular structures and tissues, allowing visualization of anatomical structures during imaging procedures.
Intravascular contrast agent for computed tomography (CT) imagingIntravascular contrast agent for angiographyIntravascular contrast agent for urographyIntravascular contrast agent for digital subtraction angiographyOral contrast agent for gastrointestinal studies (off-label)
Intravascular administration for contrast enhancement in computed tomography (CT)Excretory urographyPeripheral angiographyCerebral angiographyVentriculographyCoronary arteriography and left ventriculographyPediatric angiocardiographyOff-label: Retrograde urethrography, fistulography, sinography
Intravenous: 30-60 mL (6-12 g iodine) administered as a bolus or infusion for excretory urography; may be repeated up to a total of 125 mL (25 g iodine). Intra-arterial: Variable based on procedure, typically 8-30 mL for selective angiography.
1.2-1.5 mL/kg IV as a single dose for CT enhancement; maximum 150 mL per procedure.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours in normal renal function; prolonged in renal impairment.
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria).
Hypaque sodium is not significantly metabolized and is excreted unchanged primarily by glomerular filtration.
Not metabolized; excreted unchanged by the kidneys via glomerular filtration with minimal tubular reabsorption.
Renal: >95% unchanged via glomerular filtration within 24 hours; <5% biliary/fecal.
Renal excretion: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Minimal, <10%; primarily albumin.
Minimal (<10%); primarily albumin.
0.2-0.3 L/kg; limited to extracellular fluid.
0.2-0.3 L/kg; approximates extracellular fluid volume.
Oral: <1% (poor absorption, used for GI opacification); not applicable for IV.
Intravenous: 100%; Oral: not administered orally due to high osmolarity and GI intolerance.
GFR < 30 mL/min: Avoid use; if necessary, reduce dose by 50% and ensure adequate hydration. GFR 30-60 mL/min: Use with caution, consider lower doses and monitor renal function. GFR > 60 mL/min: No adjustment required.
eGFR <30 mL/min/1.73m2: contraindicated; eGFR 30-60: use minimum diagnostic dose, ensure adequate hydration; eGFR >60: no adjustment.
No specific adjustment for mild to moderate impairment (Child-Pugh A or B). Severe impairment (Child-Pugh C): Use with caution due to potential for delayed excretion; monitor for adverse effects.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution; Child-Pugh C: contraindicated due to risk of hepatorenal syndrome.
Intravenous: 1-2 mL/kg (0.2-0.4 g iodine/kg) for excretory urography, not to exceed 30 mL. Intra-arterial: 0.5-1 mL/kg per injection, adjusted based on procedure.
1-2 mL/kg IV not to exceed 3 mL/kg or 125 mL total, based on body weight.
Start with lower doses (e.g., 50% of adult dose) and titrate upward as needed. Monitor renal function closely due to age-related decline; ensure adequate hydration.
Reduce dose to 0.8-1.2 mL/kg IV; ensure adequate hydration; monitor renal function before and after administration.
Not for intrathecal use. Intrathecal administration may cause severe adverse reactions including convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, and death.
Not recommended for intrathecal use. Injection into the subarachnoid space may cause death, convulsions, brain damage, and other severe neurologic complications. Accidental intrathecal administration must be avoided.
["Risk of acute kidney injury, particularly in patients with pre-existing renal impairment, diabetes mellitus, or volume depletion","Anaphylactoid reactions, including anaphylaxis, bronchospasm, and hypotension","Thyroid storm in patients with hyperthyroidism or thyroid nodules","Severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome","Cardiovascular adverse events including arrhythmias and cardiac arrest","Vasovagal reactions","Extravasation leading to tissue injury"]
["Risk of serious adverse reactions including anaphylaxis, arrhythmias, myocardial infarction, and renal failure","Pre-existing renal insufficiency increases risk of contrast-induced nephropathy","Use with caution in patients with known hypersensitivity to iodine or contrast media","Patients with pheochromocytoma may develop hypertensive crisis","May exacerbate symptoms in patients with sickle cell disease","In patients with hyperthyroidism, thyroid storm may be precipitated","Test dose is not recommended to predict severe reactions"]
["Known hypersensitivity to Hypaque sodium or any of its components","History of anaphylactoid reaction to iodinated contrast media","Intrathecal administration (contraindicated due to risk of neurotoxicity)","Severe renal impairment (e.g., estimated glomerular filtration rate <30 mL/min/1.73 m²)","Concurrent administration of metformin in patients with acute kidney injury or severe renal impairment (risk of lactic acidosis)"]
["Known hypersensitivity to diatrizoate meglumine or any component","Intrathecal administration (black box warning)","Anuria or severe oliguria","Concurrent administration with other contrast agents that may cause anuria"]
Data Pending Review
Data Pending Review
No specific food interactions. Avoid alcohol for 24 hours before procedure to reduce risk of nausea and vomiting. Maintain adequate hydration with clear fluids.
No specific food interactions. Maintain adequate hydration. In patients with diabetes taking metformin, metformin should be withheld for 48 hours after contrast administration and restarted only after renal function is confirmed normal.
Hypaque Sodium 20% (diatrizoate sodium) is a radiocontrast agent. It is not known to be teratogenic in humans. However, because it contains iodine, fetal thyroid function may be affected, particularly if exposure occurs during the second or third trimester. The risk of fetal hypothyroidism is theoretical and low with single exposure. Use only if clearly needed.
HYPAQUE-M,75% (diatrizoate meglumine and diatrizoate sodium) is an iodinated radiocontrast agent. Teratogenic risk: FDA Category B. No evidence of fetal harm in animal studies; no adequate human studies. First trimester: Theoretical risk of fetal hypothyroidism due to free iodide. Second and third trimesters: Risk of neonatal hypothyroidism if administered near term; transient effects possible. Direct fetal exposure via intra-amniotic use may cause goiter.
Minimal excretion into breast milk; M/P ratio is not available. The amount ingested by a nursing infant is likely negligible. However, due to potential hypersensitivity or iodine effects, caution is advised. The manufacturer recommends discontinuing breastfeeding for 24 hours after administration, but this may be excessive. Discuss with patient.
Excreted into breast milk in minimal amounts (M/P ratio not established; estimated <1% of maternal dose). Breastfeeding is considered safe; however, theoretical risk of iodine-induced hypothyroidism in neonates. The American College of Radiology recommends no interruption of breastfeeding after contrast administration.
No specific dose adjustments are recommended for pregnancy. However, consider the increased plasma volume and renal blood flow in pregnancy; the contrast agent is renally excreted, so clearance may be slightly increased, but no dose change is typically needed. Use the lowest necessary dose.
Pregnancy may alter pharmacokinetics (increased plasma volume, renal clearance). No specific dose adjustments required for diagnostic use; use lowest necessary dose to achieve diagnostic quality. Ensure adequate hydration. Avoid repeated or high doses, especially in patients with renal impairment or near term.
Category C
Category C
Administer slowly intravenously to minimize pain and thrombosis risk. Pre-warm to body temperature to reduce viscosity. Ensure adequate hydration before and after use to prevent renal impairment. Have emergency equipment available for anaphylactoid reactions. Use with caution in patients with sickle cell disease due to risk of sickling. Contraindicated in myelography due to neurotoxicity. Check for iodine allergy history.
HYPAQUE-M 75% (diatrizoate meglumine and diatrizoate sodium) is a high-osmolar iodinated contrast medium. Pre-warming to body temperature reduces viscosity and improves patient tolerance. Adequate hydration before and after administration is critical to reduce the risk of contrast-induced nephropathy. Have emergency equipment available due to risk of anaphylactoid reactions. For patients with pheochromocytoma, consider pre-treatment with alpha-blockers to prevent hypertensive crisis.
You may experience a warm sensation or metallic taste during injection.Drink plenty of fluids before and after the procedure to protect your kidneys.Report any symptoms of allergic reaction such as hives, itching, or difficulty breathing immediately.You may have to fast for a few hours before the test depending on the procedure.Inform your doctor if you are pregnant, diabetic, or have kidney problems.You may notice a salty or metallic taste after the injection.
This contrast dye is given before imaging tests to help visualize organs and blood vessels.You may feel a warm sensation, flushing, or a metallic taste during injection; this is normal and temporary.Drink plenty of water before and after the procedure unless told otherwise by your doctor.Tell your doctor if you have allergies, asthma, diabetes, kidney disease, or are taking metformin.Inform your doctor if you are pregnant or breastfeeding.